Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Avonex PEN Satisfaction and Patients Experience Clinical Trial
- Conditions
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2013-09-16
- Lead Sponsor
- Biogen
- Target Recruit Count
- 89
- Registration Number
- NCT01366040
- Locations
- 🇨🇦
Foothills Medical Center, Calgary, Alberta, Canada
🇨🇦MUN Hospital, St. John's, Newfoundland and Labrador, Newfoundland and Labrador, Canada
🇨🇦Neuro Rive-Sud, Greenfield Park, Quebec, Canada
A Study To Assess Effects Of PF-04958242 On Bold Functional Magnetic Resonance Imaging During Working Memory Activation And Arterial Spin Labeling At Rest In Healthy Subjects
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 112
- Registration Number
- NCT01365338
- Locations
- 🇺🇸
Research Site, New Haven, Connecticut, United States
Long-Term Safety and Efficacy Study of Peginterferon Beta-1a
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-01-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1077
- Registration Number
- NCT01332019
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
A Safety Study in Healthy Volunteers of the Single-Use Autoinjector Containing Placebo of BG9418 Interferon Beta-1a With a 25-Gauge × 1-Inch Needle
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Biogen
- Target Recruit Count
- 80
- Registration Number
- NCT01313364
- Locations
- 🇨🇦
Research Site, Toronto, Ontario, Canada
Alternate Dosing Regimens of BG00012 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Target Recruit Count
- 56
- Registration Number
- NCT01281111
- Locations
- 🇺🇸
Research Site, Saint Paul, Minnesota, United States
Avonex-evaluation of Quality of Life and Convenience in Belgian Participants - The AVAIL Study
- Conditions
- First Posted Date
- 2011-01-07
- Last Posted Date
- 2015-10-20
- Lead Sponsor
- Biogen
- Target Recruit Count
- 100
- Registration Number
- NCT01272128
- Locations
- 🇧🇪
Research Site, Liège, Belgium
Safety Study of BIIB033 in Subjects With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 47
- Registration Number
- NCT01244139
- Locations
- 🇺🇸
Research Site, Centennial, Colorado, United States
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers
- First Posted Date
- 2010-11-10
- Last Posted Date
- 2019-12-24
- Lead Sponsor
- Biogen
- Target Recruit Count
- 20
- Registration Number
- NCT01238679
- Locations
- 🇸🇬
Research Site, Singapore, Singapore
Open Label Extension Study to Evaluate the Safety and Tolerability of Oral Fampridine-Sustained Release (SR) in Canadian Participants With Multiple Sclerosis Who Participated in Acorda Extension Trials.
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2014-07-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 38
- Registration Number
- NCT01235221
- Locations
- 🇨🇦
University of British Columbia, Vancouver, British Columbia, Canada
🇨🇦Ottawa Hospital General Campus, Ottawa, Ontario, Canada
🇨🇦Foothills Medical Center, Calgary, Alberta, Canada
A Pharmacokinetics (PK) and Safety Study of Oral Fampridine-PR 10 mg in Chinese, Japanese, and Caucasian Adult Healthy Volunteers
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT01215084
- Locations
- 🇭🇰
Research Site, Shatin, Hong Kong